可靶向突变对接受混合治疗(手术联合立体定向体部放疗)的非小细胞肺癌转移性硬膜外脊髓压迫患者临床结局的影响
单中心回顾性研究纳入103例病理确诊非小细胞肺癌合并脊髓转移并接受分离手术联合立体定向体部放疗的患者,中位总生存6.5个月,2年局部控制率94.6%(95%CI 89.8-99.3)。EGFR治疗初治患者于混合治疗后启动靶向治疗者总生存显著延长(HR 0.47,95%CI 0.23-0.95,P=.04)。
要点
- 混合治疗后2年局部控制率为94.6%(95%CI 89.8-99.3),仅5例(5%)出现需再手术或再放疗的进展。
- EGFR治疗初治患者于混合治疗后启动靶向治疗者总生存显著延长(HR 0.47,95%CI 0.23-0.95,P=.04)。
- 混合治疗前已启动EGFR靶向治疗未带来生存获益。
核心结论
- 非小细胞肺癌转移性硬膜外脊髓压迫接受混合治疗后2年局部控制率约为95%。
- EGFR治疗初治患者于混合治疗后启动靶向治疗者总生存显著延长。
- 混合治疗前启动EGFR靶向治疗未带来生存获益。
研究设计与样本
- 单中心回顾性研究,纳入2012年至2019年病理确诊非小细胞肺癌合并脊髓转移、因高级别硬膜外脊髓压迫或神经根压迫接受混合治疗的成人患者(≥18岁)。
- 共103例患者符合纳入标准。
主要发现
- 队列中位总生存为6.5个月。
- 5例(5%)患者在术后立体定向体部放疗后平均802天出现索引肿瘤水平疾病进展,需再手术和/或再放疗。
- 2年局部控制率为94.6%(95%CI 89.8-99.3)。
- EGFR治疗初治患者于混合治疗后启动EGFR靶向治疗者总生存显著延长(HR 0.47,95%CI 0.23-0.95,P=.04),校正吸烟状态后仍显著。
- EGFR外显子21突变与无进展生存改善相关。
关键数值与推荐
- EGFR治疗初治患者混合治疗后启动靶向治疗:总生存HR 0.47(95%CI 0.23-0.95,P=.04)。
- 2年局部控制率94.6%(95%CI 89.8-99.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In treatment of metastatic epidural spinal cord compression (MESCC), hybrid therapy, consisting of separation surgery, followed by stereotactic body radiation therapy, has become the mainstay of treatment for radioresistant pathologies, such as non-small-cell lung cancer (NSCLC). OBJECTIVE: To evaluate clinical outcomes of MESCC secondary to NSCLC treated with hybrid therapy and to identify clinical and molecular prognostic predictors. METHODS: This is a single-center, retrospective study. Adult patients (≥18 years old) with pathologically confirmed NSCLC and spinal metastasis who were treated with hybrid therapy for high-grade MESCC or nerve root compression from 2012 to 2019 are included. Outcome variables evaluated included overall survival (OS) and progression-free survival, local tumor control in the competing risks setting, surgical and radiation complications, and clinical-genomic correlations. RESULTS: One hundred and three patients met inclusion criteria. The median OS for this cohort was 6.5 months, with progression of disease noted in 5 (5%) patients at the index tumor level requiring reoperation and/or reirradiation at a mean of 802 days after postoperative stereotactic body radiation therapy. The 2-year local control rate was 94.6% (95% CI: 89.8-99.3). Epidermal growth factor receptor (EGFR) treatment-naïve patients who initiated EGFR-targeted therapy after hybrid therapy had significantly longer OS (hazard ratio 0.47, 95% CI 0.23-0.95, P = .04) even after adjusting for smoking status. The presence of EGFR exon 21 mutation was predictive of improved progression-free survival. CONCLUSION: Hybrid therapy in NSCLC resulted in 95% local control at 2 years after surgery. EGFR treatment-naïve patients initiating therapy after hybrid therapy had significantly improved survival advantage. EGFR-targeted therapy initiated before hybrid therapy did not confer survival benefit.
引用
- Chakravarthy VB, Schachner B, Amin AG, et al. The Impact of Targetable Mutations on Clinical Outcomes of Metastatic Epidural Spinal Cord Compression in Patients With Non-Small-Cell Lung Cancer Treated With Hybrid Therapy (Surgery Followed by Stereotactic Body Radiation Therapy). Neurosurgery. 2022. PMID: 36477376. doi:10.1227/neu.0000000000002247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。